Ok thanks. The updated results will carry a lot of weight.
The first round of results didn’t meet the primary objective of PFS but the secondary objectives of OS shows a significant improvement and quality of life is improved.
I’m wondering why all the analyst reports keep talking about an AIPAC ph3. The company hasn’t made any announcement about this, unless I missed something.
Also, if the AIPAC ph2b was enough for EMA registration
why is there even talk of a ph3?
is it that results aren’t quite good enough to justify the risk of a therapy not fully tested?. The recent results in other Efti trials will help. We wait in hope of the updated AIPAC results getting us over the line.
News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc, page-18
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 133736 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |